122 related articles for article (PubMed ID: 9511781)
1. Cytosine arabinoside-induced vasculitis.
Ahmed I; Chen KR; Nakayama H; Gibson LE
Mayo Clin Proc; 1998 Mar; 73(3):239-42. PubMed ID: 9511781
[TBL] [Abstract][Full Text] [Related]
2. Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia.
Bhatla D; Gerbing RB; Alonzo TA; Conner H; Ross JA; Meshinchi S; Zhai X; Zamzow T; Mehta PA; Geiger H; Perentesis J; Davies SM
Br J Haematol; 2009 Feb; 144(3):388-94. PubMed ID: 19036079
[TBL] [Abstract][Full Text] [Related]
3. Anterior uveitis associated with high-dose cytosine arabinoside.
Fintelmann RE; Qian Y; Skalet A; Jeng BH
Ocul Immunol Inflamm; 2010 Dec; 18(6):485-7. PubMed ID: 20887203
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer.
Esteva FJ; Soh LT; Holmes FA; Plunkett W; Meyers CA; Forman AD; Hortobagyi GN
Cancer Chemother Pharmacol; 2000; 46(5):382-6. PubMed ID: 11127942
[TBL] [Abstract][Full Text] [Related]
5. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P
Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584
[TBL] [Abstract][Full Text] [Related]
6. Toxic epidermal necrolysis after the use of high-dose cytosine arabinoside.
Ozkan A; Apak H; Celkan T; Yüksel L; Yildiz I
Pediatr Dermatol; 2001; 18(1):38-40. PubMed ID: 11207969
[TBL] [Abstract][Full Text] [Related]
7. High-dose cytosine arabinoside-induced cutaneous reactions.
Cetkovská P; Pizinger K; Cetkovský P
J Eur Acad Dermatol Venereol; 2002 Sep; 16(5):481-5. PubMed ID: 12428842
[TBL] [Abstract][Full Text] [Related]
8. Low dose cytosine arabinoside in the treatment of acute non-lymphoblastic leukemia.
Insiripong S; Thaisamakr S
J Med Assoc Thai; 1996 Sep; 79(9):568-71. PubMed ID: 8996985
[TBL] [Abstract][Full Text] [Related]
9. Optimal dose and schedule of consolidation in AML: is there a standard?
Schiffer CA
Best Pract Res Clin Haematol; 2014; 27(3-4):259-64. PubMed ID: 25455275
[TBL] [Abstract][Full Text] [Related]
10. Permanent cerebellar toxicity of cytosine arabinoside (Ara C) in a young woman.
Friedman JH; Shetty N
Mov Disord; 2001 May; 16(3):575-7. PubMed ID: 11391764
[TBL] [Abstract][Full Text] [Related]
11. [A case of complete remission from acute myelogenous leukemia in second relapse achieved using an intermediate-dose cytosine arabinoside (ID Ara-C) regimen].
Yoshida M; Owada N; Sasaki R; Sakamoto S; Miura Y
Gan To Kagaku Ryoho; 1986 Jan; 13(1):143-6. PubMed ID: 3455805
[TBL] [Abstract][Full Text] [Related]
12. High dose cytosine arabinoside is a major risk factor for the development of hepatosplenic candidiasis in patients with leukemia.
Woolley I; Curtis D; Szer J; Fairley C; Vujovic O; Ugoni A; Spelman D
Leuk Lymphoma; 1997 Nov; 27(5-6):469-74. PubMed ID: 9477128
[TBL] [Abstract][Full Text] [Related]
13. Cytosine-arabinoside induced bradycardia in patient with non-Hodgkin lymphoma: a case report.
Cil T; Kaplan MA; Altintas A; Pasa S; Isikdogan A
Leuk Lymphoma; 2007 Jun; 48(6):1247-9. PubMed ID: 17577797
[No Abstract] [Full Text] [Related]
14. Post-remission therapy of adult acute myeloid leukemia: high dose cytosine-arabinoside versus other consolidation regimens.
Zeremski V; Savić A
Med Pregl; 2014; 67(3-4):83-90. PubMed ID: 24961049
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
Avramis VI; Wiersma S; Krailo MD; Ramilo-Torno LV; Sharpe A; Liu-Mares W; Kowck R; Reaman GH; Sato JK
Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951
[TBL] [Abstract][Full Text] [Related]
16. [High-dose cytarabine treatment in acute leukemias and leukemic meningiosis: clinical aspects and pharmacokinetics].
Nowrousian MR; Seeber S; Miller AA; Anders C; Ohl S; Schmidt CG
Onkologie; 1985 Feb; 8(1):26-32. PubMed ID: 3885117
[TBL] [Abstract][Full Text] [Related]
17. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy for acute non-lymphocytic leukemia with low-dose cytosine arabinoside (Ara-C).
Lin SF; Liu HW; Chen TP
Nihon Ketsueki Gakkai Zasshi; 1990 Feb; 53(1):45-50. PubMed ID: 2330805
[TBL] [Abstract][Full Text] [Related]
19. Hepatotoxicity due to a possible interaction between cytosine arabinoside and dipyridamole: a case report.
Babaoglu MO; Karadag O; Saikawa Y; Altundag K; Elkiran T; Yasar U; Bozkurt A
Eur J Clin Pharmacol; 2004 Aug; 60(6):455-6. PubMed ID: 15232664
[No Abstract] [Full Text] [Related]
20. [Results of therapy with high-dose cytosine arabinoside].
Pralle H; Breithaupt H
Onkologie; 1985 Feb; 8(1):48, 50-2. PubMed ID: 3885122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
